These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9629473)

  • 1. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.
    Takashiro E; Watanabe T; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Nishigaki T; Shibayama T; Nakagawa A; Iwamoto A; Yabe Y
    Bioorg Med Chem; 1998 May; 6(5):595-604. PubMed ID: 9629473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site.
    Takashiro E; Hayakawa I; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Yamamoto I; Shibayama T; Nakagawa A; Yabe Y
    Bioorg Med Chem; 1999 Sep; 7(9):2063-72. PubMed ID: 10530956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA.
    Sakurai M; Higashida S; Sugano M; Komai T; Yagi R; Ozawa Y; Handa H; Nishigaki T; Yabe Y
    Bioorg Med Chem; 1994 Aug; 2(8):807-25. PubMed ID: 7894975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.
    Mimoto T; Terashima K; Nojima S; Takaku H; Nakayama M; Shintani M; Yamaoka T; Hayashi H
    Bioorg Med Chem; 2004 Jan; 12(1):281-93. PubMed ID: 14697794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
    De Lucca GV; Kim UT; Liang J; Cordova B; Klabe RM; Garber S; Bacheler LT; Lam GN; Wright MR; Logue KA; Erickson-Viitanen S; Ko SS; Trainor GL
    J Med Chem; 1998 Jun; 41(13):2411-23. PubMed ID: 9632373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and ex vivo anti-human immunodeficiency virus (HIV) activities of a new water-soluble HIV protease inhibitor, R-87366, containing (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid.
    Komai T; Yagi R; Suzuki-Sunagawa H; Sakurai M; Higashida S; Sugano M; Handa H; Mohri H; Yasuoka A; Oka S; Yabe Y; Nishigaki T; Kimura S; Shimada K
    Biol Pharm Bull; 1997 Feb; 20(2):175-80. PubMed ID: 9057982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease.
    Senese CL; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(4):1297-307. PubMed ID: 12870923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV; Liang J; De Lucca I
    J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.
    Kim CU; McGee LR; Krawczyk SH; Harwood E; Harada Y; Swaminathan S; Bischofberger N; Chen MS; Cherrington JM; Xiong SF; Griffin L; Cundy KC; Lee A; Yu B; Gulnik S; Erickson JW
    J Med Chem; 1996 Aug; 39(18):3431-4. PubMed ID: 8784440
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
    Le VD; Mak CC; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.
    Hidaka K; Kimura T; Sankaranarayanan R; Wang J; McDaniel KF; Kempf DJ; Kameoka M; Adachi M; Kuroki R; Nguyen JT; Hayashi Y; Kiso Y
    J Med Chem; 2018 Jun; 61(12):5138-5153. PubMed ID: 29852069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
    Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA--II. Modification of pyrrolidine ring at P1' proline.
    Komai T; Higashida S; Sakurai M; Nitta T; Kasuya A; Miyamaoto S; Yagi R; Ozawa Y; Handa H; Mohri H; Yasuoka A; Oka S; Nishigaki T; Kimura S; Shimada K; Yabe Y
    Bioorg Med Chem; 1996 Aug; 4(8):1365-77. PubMed ID: 8879560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors.
    Gupta SP; Babu MS
    Bioorg Med Chem; 1999 Nov; 7(11):2549-53. PubMed ID: 10632065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.